HN2302

· Shenzhen MagicRNA Biotechnology Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HN2302, covering 2026-03-18 to 2026-04-14. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases [Phase 1]